Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 11
2003 6
2004 11
2005 6
2006 8
2007 10
2008 15
2009 14
2010 16
2011 18
2012 21
2013 24
2014 21
2015 29
2016 32
2017 17
2018 27
2019 21
2020 14
2021 28
2022 31
2023 20
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

372 results

Results by year

Filters applied: . Clear all
Page 1
Longitudinal evaluation of SARS-CoV-2 T cell immunity over 2 years following vaccination and infection.
Juhl AK, Loksø Dietz L, Schmeltz Søgaard O, Reekie J, Nielsen H, Somuncu Johansen I, Benfield T, Wiese L, Breinholt Stærke N, Østergaard Jensen T, Olesen R, Iversen K, Fogh K, Bodilsen J, Wulff Madsen L, Olaf Lindvig S, Raben D, Dahl Andersen S, Korning Hvidt A, Rode Andreasen S, Baerends EAM, Lundgren J, Østergaard L, Tolstrup M. Juhl AK, et al. Among authors: ostergaard l. J Infect Dis. 2024 Apr 30:jiae215. doi: 10.1093/infdis/jiae215. Online ahead of print. J Infect Dis. 2024. PMID: 38687181
SARS-CoV-2 RNA and nucleocapsid antigen are blood biomarkers associated with severe disease outcomes that improve in response to remdesivir.
Singh K, Rubenstein K, Callier V, Shaw-Saliba K, Rupert A, Dewar R, Laverdure S, Highbarger H, Lallemand P, Huang ML, Jerome KR, Sampoleo R, Mills MG, Greninger AL, Juneja K, Porter D, Benson CA, Dempsey W, El Sahly HM, Focht C, Jilg N, Paules CI, Rapaka RR, Uyeki TM, Lane HC, Beigel J, Dodd LE; Adaptive COVID-19 Treatment Trial (ACTT-1) Study Group Members. Singh K, et al. J Infect Dis. 2024 Apr 24:jiae198. doi: 10.1093/infdis/jiae198. Online ahead of print. J Infect Dis. 2024. PMID: 38657001
Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19.
Aggarwal NR, Nordwall J, Braun DL, Chung L, Coslet J, Der T, Eriobu N, Ginde AA, Hayanga AJ, Highbarger H, Holodniy M, Horcajada JP, Jain MK, Kim K, Laverdure S, Lundgren J, Natarajan V, Nguyen HH, Pett SL, Phillips A, Poulakou G, Price DA, Robinson P, Rogers AJ, Sandkovsky U, Shaw-Saliba K, Sturek JM, Trautner BW, Waters M, Reilly C; ACTIV-3/TICO Study Group. Aggarwal NR, et al. Clin Infect Dis. 2024 Feb 20:ciad780. doi: 10.1093/cid/ciad780. Online ahead of print. Clin Infect Dis. 2024. PMID: 38376212
Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19.
Jensen TO, Grandits GA, Jain MK, Murray TA, Grund B, Shaw-Saliba K, Matthay MA, Abassi M, Ardelt M, Baker JV, Chen P, Dewar RL, Goodman AL, Hatlen TJ, Highbarger HC, Holodniy M, Lallemand P, Laverdure S, Leshnower BG, Looney D, Moschopoulos CD, Mugerwa H, Murray DD, Mylonakis E, Nagy-Agren S, Rehman MT, Rupert A, Stevens RA, Turville S, Weintrob A, Wick K, Lundgren J, Ko ER; ACTIV-3/TICO Study Group. Jensen TO, et al. J Infect Dis. 2024 Mar 14;229(3):671-679. doi: 10.1093/infdis/jiad446. J Infect Dis. 2024. PMID: 37948759 Free PMC article. Clinical Trial.
Discovery of neutralizing SARS-CoV-2 antibodies enriched in a unique antigen specific B cell cluster.
Lende SSF, Barnkob NM, Hansen RW, Bansia H, Vestergaard M, Rothemejer FH, Worsaae A, Brown D, Pedersen ML, Rahimic AHF, Juhl AK, Gjetting T, Østergaard L, Georges AD, Vuillard LM, Schleimann MH, Koefoed K, Tolstrup M. Lende SSF, et al. Among authors: ostergaard l. PLoS One. 2023 Sep 20;18(9):e0291131. doi: 10.1371/journal.pone.0291131. eCollection 2023. PLoS One. 2023. PMID: 37729215 Free PMC article.
Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial.
Gunst JD, Højen JF, Pahus MH, Rosás-Umbert M, Stiksrud B, McMahon JH, Denton PW, Nielsen H, Johansen IS, Benfield T, Leth S, Gerstoft J, Østergaard L, Schleimann MH, Olesen R, Støvring H, Vibholm L, Weis N, Dyrhol-Riise AM, Pedersen KBH, Lau JSY, Copertino DC Jr, Linden N, Huynh TT, Ramos V, Jones RB, Lewin SR, Tolstrup M, Rasmussen TA, Nussenzweig MC, Caskey M, Reikvam DH, Søgaard OS. Gunst JD, et al. Among authors: ostergaard l. Nat Med. 2023 Oct;29(10):2547-2558. doi: 10.1038/s41591-023-02547-6. Epub 2023 Sep 11. Nat Med. 2023. PMID: 37696935 Free PMC article. Clinical Trial.
SARS-CoV-2 vaccine-induced antibodies protect against Omicron breakthrough infection.
Baerends EAM, Hvidt AK, Reekie J, Søgaard OS, Stærke NB, Raben D, Nielsen H, Petersen KT, Juhl MR, Johansen IS, Lindvig SO, Madsen LW, Wiese L, Knudsen LS, Iversen MB, Benfield T, Iversen KK, Andersen SD, Juhl AK, Dietz LL, Andreasen SR, Fischer TK, Erikstrup C, Valentiner-Branth P, Lundgren J, Østergaard L, Tolstrup M; ENFORCE Study Group. Baerends EAM, et al. Among authors: ostergaard l. iScience. 2023 Aug 14;26(9):107621. doi: 10.1016/j.isci.2023.107621. eCollection 2023 Sep 15. iScience. 2023. PMID: 37682631 Free PMC article.
372 results